Burdock Group’s Work With BioTech Startup Captozyme Results in Successful GRAS Determination of Oxalate-Reducing Enzyme As Food Ingredient

After working with the Burdock Group to recently obtain a successful self-contained GRAS (Generally Recognized As Safe) determination for its oxalate-reducing enzyme, biotechnology company Captozyme licensed the rights for commercialization to Entring LLC, which will make it available for purchase this fall as a food ingredient. Consumers seeking a low-oxalate diet can add the virtually tasteless, odorless powder to a variety of oxalate-packed foods and beverages to help reduce the presence of the anti-nutrient.

Nephure™ Obtains Self-Affirmed GRAS Notification

Nephure™, an oxalate degrading enzyme manufactured by Captozyme, has received self-affirmed GRAS (Generally Recognized as Safe) notification by an independent panel of experts through scientific procedure following stringent US Food and Drug Administration (FDA) safety criteria. The independent panel evaluated a comprehensive dossier of characterization data and safety studies and concluded that Nephure is safe for use as a food ingredient.

Captozyme Opens Up New Headquarters

Upon graduating from the University of Florida’s Innovation Hub, local biotechnology company, Captozyme Inc., recently acquired a newly constructed facility to house their new headquarters at 1622 NW 55th Place. The company plans to consolidate all operations there during the coming months, and is proud to be part of the developing biotechnology scene of Gainesville.

Captozyme Graduates from the Innovation Hub

Captozyme is pleased to announce that they have officially graduated from the University of Florida's Innovation Hub. In the fall of 2014 Captozyme found its home at the university's incubator for start-up companies in the technology and biotechnology fields. Now, a little over 2 years later, Captozyme graduates with 14 employees and a new office and lab space in north Gainesville. 

Research Features Magazine Highlights Captozyme's CSO

The biotechnology company Captozyme is spearheading an innovative approach to nutrition to prevent the formation of painful kidney stones and other complications arising from the absorption of calcium oxalate from food. The company’s research efforts are led by Dr Qing-Shan Li, co-founder and CSO of the company.